Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

T Foukakis; A Papakonstantinou; A Matikas; NO Bengtsson; P Malmstrom; E Hedayati; GG Steger; M Untch; L Hubbert; H Johansson; M Hellstrom; M Gnant; S Loibl; Richard Greil; V Moebus; JCS Bergh

doi:10.1200/JCO.2019.37.15_suppl.553

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

T Foukakis, A Papakonstantinou, A Matikas, NO Bengtsson, P Malmstrom, E Hedayati, GG Steger, M Untch, L Hubbert, H Johansson, M Hellstrom, M Gnant, S Loibl, Richard Greil, V Moebus, JCS Bergh

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	37
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2019.37.15_suppl.553
Publication status	Published - 2019
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, IL Duration: 31 May 2019 → 4 Jun 2019

Access to Document

10.1200/JCO.2019.37.15_suppl.553

Cite this

Foukakis, T., Papakonstantinou, A., Matikas, A., Bengtsson, NO., Malmstrom, P., Hedayati, E., Steger, GG., Untch, M., Hubbert, L., Johansson, H., Hellstrom, M., Gnant, M., Loibl, S., Greil, R., Moebus, V., & Bergh, JCS. (2019). Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. JOURNAL OF CLINICAL ONCOLOGY , 37(15). https://doi.org/10.1200/JCO.2019.37.15_suppl.553

Foukakis, T ; Papakonstantinou, A ; Matikas, A et al. / Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. In: JOURNAL OF CLINICAL ONCOLOGY 2019 ; Vol. 37, No. 15.

@article{13ef7f16799b4f9f99ab94b200fa32b3,

title = "Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.",

author = "T Foukakis and A Papakonstantinou and A Matikas and NO Bengtsson and P Malmstrom and E Hedayati and GG Steger and M Untch and L Hubbert and H Johansson and M Hellstrom and M Gnant and S Loibl and Richard Greil and V Moebus and JCS Bergh",

year = "2019",

doi = "10.1200/JCO.2019.37.15_suppl.553",

language = "English",

volume = "37",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 31-05-2019 Through 04-06-2019",

}

Foukakis, T, Papakonstantinou, A, Matikas, A, Bengtsson, NO, Malmstrom, P, Hedayati, E, Steger, GG, Untch, M, Hubbert, L, Johansson, H, Hellstrom, M, Gnant, M, Loibl, S, Greil, R, Moebus, V & Bergh, JCS 2019, 'Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.', JOURNAL OF CLINICAL ONCOLOGY , vol. 37, no. 15. https://doi.org/10.1200/JCO.2019.37.15_suppl.553

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. / Foukakis, T; Papakonstantinou, A; Matikas, A et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 37, No. 15, 2019.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

AU - Foukakis, T

AU - Papakonstantinou, A

AU - Matikas, A

AU - Bengtsson, NO

AU - Malmstrom, P

AU - Hedayati, E

AU - Steger, GG

AU - Untch, M

AU - Hubbert, L

AU - Johansson, H

AU - Hellstrom, M

AU - Gnant, M

AU - Loibl, S

AU - Greil, Richard

AU - Moebus, V

AU - Bergh, JCS

PY - 2019

Y1 - 2019

U2 - 10.1200/JCO.2019.37.15_suppl.553

DO - 10.1200/JCO.2019.37.15_suppl.553

M3 - Abstract (Journal)

SN - 0732-183X

VL - 37

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 31 May 2019 through 4 June 2019

ER -

Foukakis T, Papakonstantinou A, Matikas A, Bengtsson NO, Malmstrom P, Hedayati E et al. Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. JOURNAL OF CLINICAL ONCOLOGY . 2019;37(15). doi: 10.1200/JCO.2019.37.15_suppl.553